These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8355677)

  • 1. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression.
    Unger T; Mietz JA; Scheffner M; Yee CL; Howley PM
    Mol Cell Biol; 1993 Sep; 13(9):5186-94. PubMed ID: 8355677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel p53 functional domain that is necessary for efficient growth suppression.
    Walker KK; Levine AJ
    Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15335-40. PubMed ID: 8986812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53: Multiple Facets of a Rubik's Cube.
    Zhang Y; Lozano G
    Annu Rev Cancer Biol; 2017 Mar; 1():185-201. PubMed ID: 30775651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cDNA Cloning of Feline PIWIL1 and Evaluation of Expression in the Testis of the Domestic Cat.
    Stalker L; Backx AG; Tscherner AK; Russell SJ; Foster RA; LaMarre J
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide and protein chemistry approaches to study the tumor suppressor protein p53.
    Chatterjee C; Singh SK
    Org Biomol Chem; 2022 Jul; 20(28):5500-5509. PubMed ID: 35786742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ISG15 Deficiency Enhances HIV-1 Infection by Accumulating Misfolded p53.
    Osei Kuffour E; König R; Häussinger D; Schulz WA; Münk C
    mBio; 2019 Aug; 10(4):. PubMed ID: 31455647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy Resistance in Advanced Ovarian Cancer Patients.
    Pokhriyal R; Hariprasad R; Kumar L; Hariprasad G
    Biomark Cancer; 2019; 11():1179299X19860815. PubMed ID: 31308780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Casein Kinase II by Gallic Acid Induces BIK-BAX/BAK-Mediated ER Ca
    Lin ML; Chen SS
    Front Physiol; 2017; 8():761. PubMed ID: 29033852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 is an important regulator of CCL2 gene expression.
    Tang X; Asano M; O'Reilly A; Farquhar A; Yang Y; Amar S
    Curr Mol Med; 2012 Sep; 12(8):929-43. PubMed ID: 22804246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome instability and deregulated proliferation: an unavoidable duo.
    Coschi CH; Dick FA
    Cell Mol Life Sci; 2012 Jun; 69(12):2009-24. PubMed ID: 22223110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein.
    Lee CW; Martinez-Yamout MA; Dyson HJ; Wright PE
    Biochemistry; 2010 Nov; 49(46):9964-71. PubMed ID: 20961098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2.
    Ferreon JC; Lee CW; Arai M; Martinez-Yamout MA; Dyson HJ; Wright PE
    Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6591-6. PubMed ID: 19357310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP.
    Lee CW; Arai M; Martinez-Yamout MA; Dyson HJ; Wright PE
    Biochemistry; 2009 Mar; 48(10):2115-24. PubMed ID: 19220000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of p53 and Rb in ovarian cancer.
    Corney DC; Flesken-Nikitin A; Choi J; Nikitin AY
    Adv Exp Med Biol; 2008; 622():99-117. PubMed ID: 18546622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific.
    Smith JM; Stubbert LJ; Hamill JD; McKay BC
    Neoplasia; 2007 Dec; 9(12):1057-65. PubMed ID: 18084613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.
    Dreyfus DH; Nagasawa M; Gelfand EW; Ghoda LY
    BMC Immunol; 2005 Jun; 6():12. PubMed ID: 15969767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 activation domain 1 is essential for PUMA upregulation and p53-mediated neuronal cell death.
    Cregan SP; Arbour NA; Maclaurin JG; Callaghan SM; Fortin A; Cheung EC; Guberman DS; Park DS; Slack RS
    J Neurosci; 2004 Nov; 24(44):10003-12. PubMed ID: 15525786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication of damaged DNA in vitro is blocked by p53.
    Zhou J; Prives C
    Nucleic Acids Res; 2003 Jul; 31(14):3881-92. PubMed ID: 12853603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-amino-acid segment, present in type s2 but not type s1 Helicobacter pylori VacA proteins, abolishes cytotoxin activity and alters membrane channel formation.
    McClain MS; Cao P; Iwamoto H; Vinion-Dubiel AD; Szabo G; Shao Z; Cover TL
    J Bacteriol; 2001 Nov; 183(22):6499-508. PubMed ID: 11673417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.
    Matas D; Sigal A; Stambolsky P; Milyavsky M; Weisz L; Schwartz D; Goldfinger N; Rotter V
    EMBO J; 2001 Aug; 20(15):4163-72. PubMed ID: 11483519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.